Skip to content
Fiscal Receipts

Senate LDA lobbying filing

PFIZER INC.

Registrant: PFIZER INC. Year: 2025 Period: First Quarter Type: Q1

View on lda.senate.gov ↗

Reported income

not reported

Reported expenses

$4.24M

Tracked program mentions5

Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.

  • Amphibious Combat Vehicle Family of Vehicles2025matched: “2025PE code cited directly

    H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the…

  • Making, Maintaining, Supply Chain and Logistics0602025Ematched: “Supply|Chainmatched 2+ title words

    HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other…

  • SPQ-9B Radar2026matched: “2026PE code cited directly

    H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the…

  • SSTD2213matched: “2213PE code cited directly

    HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other…

  • Teleport Program14matched: “14PE code cited directly

    H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the…

Lobbying activities5

  • Budget/AppropriationsBUD

    H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 Budget Reconciliation

  • Health IssuesHCR

    S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs

  • Medicare/MedicaidMMM

    S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access

  • Taxation/Internal Revenue CodeTAX

    H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 VICP Reform and Excise Tax Tax Cuts and Jobs Act (TCJA) Comprehensive Corporate Tax Reform

  • Trade (domestic/foreign)TRD

    HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other Import Restrictions with Respect to Medical Goods Medical Supply Chain Resiliency Act International Supply Chain Tariffs Non-Tariff Trade Barriers

Lobbyists8

  • ANGELA WILES
  • CATHERINE ROBINSON
  • ELISSA ALBEN
  • EMILY MUELLER
  • JENNIFER WALTON
  • MATTHEW STROIA
  • PAULA BURG
  • STEPHEN CLAEYS

Source: U.S. Senate Lobbying Disclosure Act database. Dollar figures (underlined) cite the filing record on lda.senate.gov — click to view the citation. Amounts shown as “not reported” are absent from the filing itself.